Laboratory reports are available for selected lots. Check each report for its result and stated method.
GLP-1 Semaglutide
≥98% Purity
Class-level spec; selected lots third-party tested
COA Available
Batch report on request · HPLC identity check
Size
10mg
= Lab report published
€39.99
1
Total: €39.99
Free shipping on orders over €200
- If a product does not match the specification on its published COA, contact us with your batch number: we investigate against the lot report and replace any product that fails it, at no cost to you.
- Contact us within 48 hours of delivery with photos of the outer box, inner packing, and any affected vials with labels legible. Confirmed transit damage is replaced at no cost to you.
3–7 days most of the EU · 10–14 Nordics/Baltics
Standard EU from €4.99 · core EU GLS €17.99 · Dispatched within 1–2 business days · Free shipping over €200 · no customs paperwork (EU).
How Paysera and SEPA work
- Pay: send a manual SEPA transfer using the IBAN we email you, or approve a SEPA transfer via Paysera where offered.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders typically ship within 1–2 business days.
Card payments are not currently offered.
Research-grade Semaglutide (GLP-1 analogue) for laboratory and analytical research. For research purposes only. Not for human consumption.
Volume Pricing
Applied automatically at checkout
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €39.99 | €39.99 | — |
| 3+ | €37.99 | €113.97 | 5% off |
| 5+ Most Popular | €35.99 | €179.96 | 10% off |
| 10+ | €33.99 | €339.92 | 15% off |
Class-level specification on record; independent testing on selected lots.
Dispatched within 1–2 business days, shipping from €4.99 in the EU.
Ships across the EU plus Switzerland and the UK where permitted.
GLP-1 (Semaglutide)
Semaglutide is a prescription GLP-1 receptor agonist used for weight loss and for managing type 2 diabetes. It reduces appetite and calorie intake, leading to sustained weight loss for many patients. In type 2 diabetes it improves glycemic control by increasing glucose‑dependent insulin secretion and lowering glucagon, reducing fasting/postprandial glucose and HbA1c. Clinical studies show cardiovascular risk reduction in some patients and additional benefits such as lower blood pressure, improved lipids, and reduced liver fat. Many users report better energy and quality of life alongside metabolic improvements.
What Is Semaglutide?
Semaglutide is a type of GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a naturally occurring hormone. Semaglutide works through pathways involved in appetite and blood sugar regulation. It can reduce your appetite and help you feel fuller for longer, supporting efforts to lose weight alongside dietary changes and physical activity.
A GLP-1 agonist is not suitable for everyone. Choosing a GLP-1 medication involves considering the licensed use, potential benefits, side effects and ongoing monitoring.
| Product | Form | Main treatment indication |
|---|---|---|
| Wegovy injection | Weekly injection pen | Weight management in eligible patients |
| Wegovy pill | Daily semaglutide tablet | Weight management in eligible adults |
| Ozempic | Weekly injection | Type 2 diabetes |
| Rybelsus | Daily tablet | Type 2 diabetes |
Ozempic is prescribed to treat type 2 diabetes; it is not the semaglutide brand approved for weight management. Ozempic should not be treated as interchangeable with Wegovy without a prescribing review.
Wegovy Injection and Wegovy Pill
Wegovy offers an injection option and an oral alternative. The Wegovy pill launched in EU in July 2026 following approval in June, so describing it as available only in the United States is outdated. Local stock and prescribing arrangements still need confirmation.
A weight loss injection and a tablet have different administration requirements. Follow the instructions for the exact product prescribed rather than switching between formulations yourself. When comparing private providers, check the full treatment cost, including consultations, medicine supply and follow-up support.
Is Semaglutide Available on the NHS?
Semaglutide is available on the NHS for eligible patients, but access depends on the indication and relevant prescribing criteria. For weight loss, NICE guidance recommends treatment through a specialist weight management service, alongside dietary and activity support, for a maximum of two years.
Eligibility generally includes a weight-related health condition and specified BMI criteria. Lower BMI thresholds apply to some ethnic backgrounds. NHS arrangements can differ across Europe, so ask your healthcare team about the applicable referral pathway. Approval of a new formulation does not automatically establish NHS access to it.
How Well Does Semaglutide Work for Weight Loss?
The STEP 1 trial examined once-weekly semaglutide in adults with overweight or obesity who did not have diabetes. Published in the New England Journal of Medicine, it reported average weight loss of 14.9% with semaglutide 2.4 mg versus 2.4% with placebo after 68 weeks. Both groups received lifestyle support.
| Trial group | Mean change in body weight | Duration |
|---|---|---|
| Semaglutide 2.4 mg weekly | −14.9% | 68 weeks |
| Placebo | −2.4% | 68 weeks |
These results show that semaglutide can help eligible patients lose weight, but individual outcomes vary. They should not be presented as guaranteed results or directly compared with unrelated trials using different doses, populations and methods.
Choosing and Monitoring Treatment
GLP-1 medications for weight loss should form part of an individual care plan. For people with type 2 diabetes, treatment decisions also involve glucose control and other prescribed medicines. A GLP-1 receptor agonist may address several clinical goals, but the product and dose must match the indication.
Before taking GLP-1 treatment, read the patient information leaflet. Common side effects include nausea, vomiting, diarrhoea and constipation. Seek urgent medical attention if you develop severe, persistent abdominal pain, particularly if it spreads to your back.
Whether considering weight loss injections or oral treatment, discuss the options with your prescriber. Regular review helps assess progress, tolerability and whether semaglutide remains appropriate throughout your weight loss journey.
Related Studies:
Product Specifications
- Form: Lyophilized powder
- Purity: ≥98% (class-level specification)
- Storage: −20°C, protected from light
- Intended use: Laboratory research only
- Documentation: Batch certificate of analysis on request
COA Analysis
Selected lots are independently tested. Request the certificate for your batch number before the material enters an assay. Identity should match the stated sequence on the vial label.
For research purposes only. Not for human consumption.
Handling & Storage
Check the lot number against the certificate before the material enters an assay. Reconstitute only when the protocol calls for a working solution, using the solvent and concentration that protocol specifies. A prepared solution is not assumed to have the same storage life as the dry vial.
Store sealed vials at −20°C, protected from light and moisture. For research use only. Not for human or animal administration.
